miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2

Published:2019-12 Issue: Volume:18 Page:627-637
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Zhang Liang,Huang Ping,Li Qing,Wang Dong,Xu Cheng-Xiong

Funder

Startup Fund for Talented Scholars of Daping Hospital and Research Institute of Surgery, Third Military Medical University

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference40 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019

2. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma;Meng;Clin. Cancer Res.,2013

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

4. Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma;Fillon;CA Cancer J. Clin.,2018

5. DNA methylation markers and early recurrence in stage I lung cancer;Brock;N. Engl. J. Med.,2008

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression;Molecular Biology Reports;2024-06-01

2. MiR-134-5p inhibits the malignant phenotypes of osteosarcoma via ITGB1/MMP2/PI3K/Akt pathway;Cell Death Discovery;2024-04-25

3. Self-assembled miR-134-5p inhibitor nanoparticles ameliorate experimental bronchopulmonary dysplasia (BPD) via suppressing ferroptosis;Microchimica Acta;2023-11-30

4. LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis;Journal of Translational Medicine;2023-11-26

5. Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer;Cellular and Molecular Life Sciences;2023-10-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3